Zobrazeno 1 - 10
of 70
pro vyhledávání: '"Thomas Geer"'
Autor:
Sonia Jaramillo, Lucian Le Cornet, Markus Kratzmann, Johannes Krisam, Martin Görner, Mathias Hänel, Christoph Röllig, Maxi Wass, Sebastian Scholl, Mark Ringhoffer, Alexander Reichart, Björn Steffen, Sabine Kayser, Jan-Henrik Mikesch, Kerstin Schaefer-Eckart, Jörg Schubert, Thomas Geer, Sonja Martin, Meinhard Kieser, Tim Sauer, Katharina Kriegsmann, Michael Hundemer, Hubert Serve, Martin Bornhäuser, Carsten Müller-Tidow, Richard F. Schlenk
Publikováno v:
Trials, Vol 24, Iss 1, Pp 1-15 (2023)
Abstract Background About 50% of older patients with acute myeloid leukemia (AML) fail to attain complete remission (CR) following cytarabine plus anthracycline-based induction therapy. Salvage chemotherapy regimens are based on high-dose cytarabine
Externí odkaz:
https://doaj.org/article/429cfaca4e8047249e5f275e8cfc363c
Autor:
Katja Sockel, Anke Mütherig, Martina Crysandt, Mathias Hänel, Richard Noppeney, Kerstin Schaefer-Eckart, Martin Kaufmann, Christoph Röllig, Johannes Schetelig, Sven Zukunft, Frank Fiebig, Aristoteles Giagounidis, Sebastian Scholl, Andreas Lück, Kathrin Rieger, Katharina Götze, Thomas Geer, Philipp Kiewe, Carsten Müller-Tidow, Hubert Serve, Claudia Baldus, Ulrich Kaiser, Stefan Mahlmann, Burkhard Schmidt, Stefani Parmentier, Thomas Illmer, Ruth Seggewiß-Bernhardt, Alexander Kiani, Hartmut Linde, Heinz Dürk, Michael Kramer, Desiree Kunadt, Katharina Schmidt-Brücken, Jana Hase, Susann Helas, Jan Moritz Middeke, Malte von Bonin, Uta Oelschlaegel, Gerhard Ehninger, Christian Thiede, Martin Bornhauser, Uwe Platzbecker
Publikováno v:
HemaSphere, Vol 7, p e09759ad (2023)
Externí odkaz:
https://doaj.org/article/acd4818220c24cd7946a96fe0e80f14b
Autor:
Sonia Jaramillo, Johannes Krisam, Lucian Le Cornet, Markus Kratzmann, Lukas Baumann, Tim Sauer, Martina Crysandt, Andreas Rank, Dirk Behringer, Lino Teichmann, Martin Görner, Ralf-Ulrich Trappe, Christoph Röllig, Stefan Krause, Maher Hanoun, Olaf Hopfer, Gerhard Held, Sebastian Buske, Lars Fransecky, Sabine Kayser, Christoph Schliemann, Kerstin Schaefer-Eckart, Yousef Al-Fareh, Jörg Schubert, Thomas Geer, Martin Kaufmann, Arne Brecht, Dirk Niemann, Meinhard Kieser, Martin Bornhäuser, Uwe Platzbecker, Hubert Serve, Claudia D. Baldus, Carsten Müller-Tidow, Richard F. Schlenk
Publikováno v:
Trials, Vol 22, Iss 1, Pp 1-13 (2021)
Abstract Background Overall survival remains poor in older patients with acute myeloid leukemia (AML) with less than 10% being alive after 5 years. In recent studies, a significant improvement in event-free, relapse-free and overall survival was show
Externí odkaz:
https://doaj.org/article/de39e7989b1540d2a1eb5143a0cffc57
Autor:
Christian Michel, Andreas Burchert, Andreas Hochhaus, Susanne Saussele, Andreas Neubauer, Michael Lauseker, Stefan W. Krause, Hans-Jochem Kolb, Dieter Kurt Hossfeld, Christoph Nerl, Gabriela M. Baerlocher, Dominik Heim, Tim H Brümmendorf, Alice Fabarius, Claudia Haferlach, Brigitte Schlegelberger, Leopold Balleisen, Maria-Elisabeth Goebeler, Mathias Hänel, Anthony Ho, Jolanta Dengler, Christiane Falge, Robert Möhle, Stephan Kremers, Michael Kneba, Frank Stegelmann, Claus-Henning Köhne, Hans-Walter Lindemann, Cornelius F. Waller, Karsten Spiekermann, Wolfgang E. Berdel, Lothar Müller, Matthias Edinger, Jiri Mayer, Dietrich W. Beelen, Martin Bentz, Hartmut Link, Bernd Hertenstein, Roland Fuchs, Martin Wernli, Frank Schlegel, Rudolf Schlag, Maike de Wit, Lorenz Trümper, Holger Hebart, Markus Hahn, Jörg Thomalla, Christof Scheid, Philippe Schafhausen, Walter Verbeek, Michael J. Eckart, Winfried Gassmann, Michael Schenk, Peter Brossart, Thomas Wündisch, Thomas Geer, Stephan Bildat, Erhardt Schäfer, Joerg Hasford, Rüdiger Hehlmann, Markus Pfirrmann
Publikováno v:
Haematologica, Vol 104, Iss 5 (2019)
Standard first-line therapy of chronic myeloid leukemia is treatment with imatinib. In the randomized German Chronic Myeloid Leukemia-Study IV, more potent BCR-ABL inhibition with 800 mg (‘high-dose’) imatinib accelerated achievement of a deep mo
Externí odkaz:
https://doaj.org/article/8f2e3c990dda4c23bf1aba8a1a3b48ba
Autor:
Susanne Schnittger, Ulrike Bacher, Claudia Haferlach, Thomas Geer, Peter Müller, Johann Mittermüller, Petro Petrides, Rudolf Schlag, Reiner Sandner, Johannes Selbach, Hans Rainer Slawik, Hans Werner Tessen, Jürgen Wehmeyer, Wolfgang Kern, Torsten Haferlach
Publikováno v:
Haematologica, Vol 94, Iss 3 (2009)
To further characterize JAK2 exon 12 mutations, we performed molecular screening in 409 patients with polycythemia vera or unclear erythrocytosis with unmutated JAK2V617. The frequency of JAK2exon12 mutations was 10/63 (15.9%) in PV but only 5/346 (1
Externí odkaz:
https://doaj.org/article/ad631b7757754b96921889d772a25d4e
Autor:
Hartmut Goldschmidt, Elias K Mai, Uta Bertsch, Roland Fenk, Eva Nievergall, Diana Tichy, Britta Besemer, Jan Dürig, Roland Schroers, Ivana von Metzler, Mathias Hänel, Christoph Mann, Anne M Asemissen, Bernhard Heilmeier, Niels Weinhold, Stefanie Huhn, Katharina Kriegsmann, Steffen P Luntz, Tobias A W Holderried, Karolin Trautmann-Grill, Deniz Gezer, Maika Klaiber-Hakimi, Martin Müller, Cyrus Khandanpour, Wolfgang Knauf, Christof Scheid, Markus Munder, Thomas Geer, Hendrik Riesenberg, Jörg Thomalla, Martin Hoffmann, Marc S Raab, Hans J Salwender, Katja C Weisel, Joachim Behringer, Helga Bernhard, Christiane Bernhardt, Igor W Blau, Claus Bolling, Daniel Debatin, Gerrit Dingeldein, Barbara Ferstl, Claudia Fest, Stefan Fronhoffs, Stephan Fuhrmann, Tobias Gaska, Martin Görner, Ullrich Graeven, Jochen Grassinger, Michael Heinsch, Gerhard Held, Olaf Hopfer, Peter Immenschuh, Dominic Kaddu-Mulindwa, Martine Klausmann, Stefan Klein, Yon-Dschun Ko, Georg Köchling, Michael Koenigsmann, Philippe Kostrewa, Doris Maria Kraemer, Stephan Kremers, Martin Kropff, Paul La Rosée, Rolf Mahlberg, Uwe Martens, Michael Neise, Holger Nückel, Wolfram Pönisch, Maria Procaccianti, Mohammed R Rafiyan, Peter Reimer, Armin Riecke, Mathias Rummel, Volker Runde, Markus Schaich, Christoph Scheid, Martin Schmidt-Hieber, Stefan Schmitt, Daniel Schöndube, Andreas Schwarzer, Peter Staib, Heike Steiniger, Dirk Sturmberg, Hans-Joachim Tischler, Arne Trummer, Barbara Tschechne, Walter Verbeek, Bettina Whitlock, Maike de Wit, Matthias Zaiß, Carsten Ziske
Publikováno v:
The Lancet Haematology. 9:e810-e821
Anti-CD38 monoclonal antibodies have consistently shown increased efficacy when added to standard of care for patients with multiple myeloma. We aimed to assess the efficacy of isatuximab in addition to lenalidomide, bortezomib, and dexamethasone in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa4e06ca167ce956ab3c750cb5371c4d
https://doi.org/10.1016/s2352-3026(22)00263-0
https://doi.org/10.1016/s2352-3026(22)00263-0
Autor:
Katharina Kohlbrenner, Norbert Galuschek, Alice Fabarius, Marcel Reiser, Klaus Fenchel, Eva Eßeling, Thomas Göhler, Thomas Geer, Reinhard Depenbusch, Ivo Talah Azeh, Erik Engel, Richard Hansen, Hans-Walter Lindemann, Jürgen Anhuf, Paul Jehner, Maisun Abu-Samra, Markus Ritter, Norbert Gattermann, Henning Pelz, Stefan Fuxius, Burkhard Oswald, Gabriela M Baerlocher, Tim H.H. Brummendorf, Dominik Heim, Philipp le Coutre, Andreas Burchert, Dietger Niederwieser, Hans Tesch, Wolf-Karsten Hofmann, Andreas Hochhaus, Rüdiger Hehlmann, Susanne Saussele
Publikováno v:
Blood. 140:947-949
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ca1757a83ecb5fe97c678688b2b0c619
https://doi.org/10.1182/blood-2022-159412
https://doi.org/10.1182/blood-2022-159412
Autor:
Etienne Buscail, Manon Bolzinger, Jason Shourick, Marie Laure Lier, Phillipe Sautier, Magali Delhoste, Fabrice Muscari, Nicolas Carrère, Charlotte Maulat, Yoann Dalmas, Pierre Brinas, Thomas Prudhomme, Cyril Podio, Charles-Henri Houze-Cerfon, Odile Rauzy, Thomas Geeraerts, Olivier Abbo
Publikováno v:
BMC Medical Education, Vol 24, Iss 1, Pp 1-9 (2024)
Abstract Introduction Since the early 2000's, the appeal of certain operating room specialties has decreasedamong medical school graduate students. The recent reform of the second and third cycles of medical studies in France provides an opportunity
Externí odkaz:
https://doaj.org/article/a4eaa7e9bc124094aa8fe442d7271f8f
Autor:
Sonia Jaramillo, Lucian Le Cornet, Markus Kratzmann, Johannes Krisam, Martin Görner, Mathias Hänel, Christoph Röllig, Maxi Wass, Sebastian Scholl, Mark Ringhoffer, Alexander Reichart, Björn Steffen, Sabine Kayser, Jan-Henrik Mikesch, Kerstin Schaefer-Eckart, Jörg Schubert, Thomas Geer, Sonja Martin, Meinhard Kieser, Tim Sauer, Katharina Kriegsmann, Michael Hundemer, Hubert Serve, Martin Bornhäuser, Carsten Müller-Tidow, Richard F. Schlenk
Background: About 50% of older patients with acute myeloid leukemia (AML) fail to attain complete remission (CR) following cytarabine plus anthracycline-based induction therapy. Salvage chemotherapy regimens are based on high dose cytarabine (HiDAC),
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e51c112431cc5fdbcd02ca3005cae904
https://doi.org/10.21203/rs.3.rs-1117424/v1
https://doi.org/10.21203/rs.3.rs-1117424/v1
Autor:
Christiane Pott, Christian Koenecke, Fabian Acker, Corinna Leng, Léandra Caillé, Andrea Kerkhoff, Dimitrios Mougiakakos, Georg Hess, Sascha Dietrich, Jan-Moritz Middeke, Udo Holtick, Thomas Geer, Jens M. Chemnitz, Andreas Huettmann, Eva Kaebisch, Ruediger Liersch, Rainer Claus, Stephan Fuhrmann, Donnacha Fitzgerald, Uta Brunnberg, Lars Bullinger, Nora Liebers, Arne Trummer, Ralf Ulrich Trappe, Niklas Gebauer, Georg Lenz, Manfred Welslau, Gerald Wulf, Carsten Mueller-Tidow, Stefan Fuxius, Johannes Duell, Peter Dreger, Stephanie Mayer, Bertram Glass, Daniel Noerenberg, Thomas Weber, Christian Spoer, Roald Pfannes, Ulrich Keller
Publikováno v:
Blood Adv
The antibody-drug conjugate polatuzumab vedotin (pola) has recently been approved in combination with bendamustine and rituximab (pola-BR) for patients with refractory or relapsed (r/r) large B-cell lymphoma (LBCL). To investigate the efficacy of pol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc9ee0869bc913161af8eed2ce06a7ab
http://edoc.mdc-berlin.de/20400/7/20400suppl.pdf
http://edoc.mdc-berlin.de/20400/7/20400suppl.pdf